Georgia Expands Medical Cannabis Access With New Qualifying Conditions and Dispensary Licenses

Georgia has long been one of the most restrictive medical cannabis states in the country. Since the passage of Hailey’s Hope Act in 2015, which allowed patients with certain conditions to possess low-THC cannabis oil, the state’s program has been plagued by implementation delays, an extremely limited list of qualifying conditions, and a supply infrastructure so constrained that many registered patients had no legal way to actually obtain the medicine they were authorized to use.

That changed in significant ways this month. Governor Brian Kemp signed HB 842 on April 3, a comprehensive expansion bill that adds new qualifying conditions, increases the number of production and dispensary licenses, raises the THC cap on medical cannabis oil, and establishes a framework for in-state cultivation that could finally close the gap between patient need and product availability.

What the Expansion Includes

New Qualifying Conditions

Georgia’s original medical cannabis law limited access to patients with a narrow set of conditions, primarily focused on seizure disorders, terminal cancer, and a handful of other severe diagnoses. HB 842 adds the following to the list of qualifying conditions:

• Chronic pain lasting more than six months and documented by a physician
• Anxiety disorders (generalized anxiety disorder, social anxiety disorder, panic disorder)
• Insomnia and other clinically diagnosed sleep disorders
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis)
• Autism spectrum disorder (expanding beyond the previous pediatric-only provision to include adults)
• Chronic migraines
• Substance use disorder (specifically for opioid use disorder, as an adjunct to medication-assisted treatment)

The addition of chronic pain and anxiety disorders is particularly significant. These are among the most commonly cited reasons for cannabis use across all state programs and are expected to dramatically increase the number of Georgia patients who qualify. The Georgia Department of Public Health estimates that eligible patients could grow from approximately 30,000 to more than 200,000 within the first year.

Increased THC Cap

The previous law limited medical cannabis oil to 5% THC — a threshold that patient advocates and physicians consistently argued was too low to provide meaningful relief for many conditions. HB 842 raises the cap to 10% THC for most conditions and allows up to 15% THC for terminal illness, intractable pain, and certain other severe diagnoses at physician discretion.

While these caps remain well below what is available in most medical cannabis states (and far below recreational markets), the increase gives physicians and patients a broader range of therapeutic options. Research suggests that for conditions like chronic pain and sleep disorders — including emerging evidence on cannabinoids for sleep apnea — the effective dose often requires THC concentrations above 5%.

New Dispensary and Production Licenses

Perhaps the most impactful provision is the expansion of the production and retail infrastructure. Georgia previously authorized only six production licenses for its Class 1 and Class 2 manufacturers. HB 842 adds eight new production licenses and, critically, authorizes up to 40 standalone dispensary locations across the state — up from the approximately 15 locations that existing license holders were operating.

The new dispensary licenses will be distributed with geographic equity provisions, ensuring that rural areas and underserved communities have access. At least 25% of new licenses are reserved for applicants who qualify under the bill’s social equity provisions, which prioritize individuals from communities disproportionately affected by cannabis prohibition.

Possession Limit Increase

Registered patients can now possess up to 40 fluid ounces of low-THC oil, up from the previous limit of 20 fluid ounces. For patients managing chronic conditions who consume cannabis oil daily, the previous limit was restrictive enough to require frequent dispensary visits — a particular burden for patients in rural areas far from existing dispensary locations.

The Implementation Timeline

The new qualifying conditions take effect immediately, and the Georgia Access to Medical Cannabis Commission (GAMCC) has indicated that physicians can begin certifying patients under the expanded conditions starting May 1, 2026. The dispensary licensing process is expected to take longer. The GAMCC will publish application guidelines by July 1, with a 90-day application window. License awards are anticipated by the end of 2026, with new dispensaries expected to begin operating in early 2027.

The production license expansion follows a similar timeline but may move slightly faster since the state can leverage the existing regulatory framework established for its original six license holders.

Reaction and Context

Patient advocacy groups, which have lobbied for expansion for years, welcomed the bill while noting that Georgia still lags behind most other medical cannabis states.

“This is meaningful progress for patients who have been waiting for years to access a medicine that could change their lives,” said Catherine Walker, executive director of the Georgia Cannabis Patients Alliance. “But we also recognize that a 10% THC cap and no access to whole-plant flower still limits what physicians can do for their patients. We will continue to push for a program that fully reflects the medical evidence.”

The Georgia Chamber of Commerce also endorsed the expansion, citing the economic potential. A state-commissioned economic impact study estimated that the expanded program could generate $180 million in annual retail sales and create approximately 2,500 direct jobs within three years.

Law enforcement groups were more measured. The Georgia Sheriffs’ Association did not oppose the bill but issued a statement emphasizing the need for robust enforcement of the THC caps and a clear distinction between legally possessed medical cannabis oil and illicit cannabis products.

How Georgia Compares

Even after HB 842, Georgia’s medical cannabis program remains more restrictive than most. The state does not allow whole-plant flower, smokable products, or edibles — only low-THC oil. There is no home cultivation provision, and the THC cap is among the lowest of any medical cannabis state.

However, the trajectory is clear. Georgia has moved from one of the most inaccessible medical cannabis programs in the country to one that, while still restrictive, serves a meaningfully broader patient population. The addition of chronic pain and anxiety as qualifying conditions brings Georgia closer to the standard set by states like Florida, Pennsylvania, and Ohio.

For cannabis businesses watching the landscape of state-by-state expansion — and for the investors funding cannabis growth — Georgia represents a familiar pattern: slow initial rollout followed by gradual expansion as patient demand, political will, and economic incentives align.

What Patients Need to Do

Georgia residents who believe they may qualify under the new conditions should take the following steps:

1. Consult a physician: Any Georgia-licensed physician can certify a patient for the medical cannabis program. Unlike some states, Georgia does not require physicians to complete a separate certification course, though the GAMCC maintains a voluntary registry of physicians who are experienced with the program.

2. Register with the Low-THC Oil Registry: After receiving a physician certification, patients must register through the Georgia Department of Public Health’s Low-THC Oil Registry. Registration is free and can be completed online.

3. Obtain a Low-THC Oil Registry Card: Upon approval, patients receive a registry card that authorizes possession and use of low-THC cannabis oil. The card must be carried when in possession of cannabis oil.

4. Purchase from a licensed dispensary: Products can only be legally obtained from licensed dispensaries in Georgia. While cannabis apps like Weedmaps track dispensary locations in many states, Georgia’s limited number of current dispensary locations makes checking the GAMCC’s official dispensary list the most reliable starting point.

Looking Ahead

The broader significance of Georgia’s expansion extends beyond its borders. As a large, politically conservative Southern state, Georgia’s willingness to substantially expand medical cannabis access sends a signal that resonates with legislators in other holdout states. Mississippi, which implemented its own medical cannabis program in 2023, has been watching Georgia closely and may introduce similar expansion legislation in its next session.

The expansion also has implications for the ongoing federal conversation. As more states expand access and the evidence base grows — from neuroprotection research to inflammation studies — the political case for federal reform becomes harder to resist. Georgia’s HB 842, while modest by the standards of established cannabis states, is another brick in the foundation of an increasingly undeniable national consensus.